Quantcast
Last updated on April 24, 2014 at 12:48 EDT

Latest Acute myeloid leukemia Stories

2013-12-09 20:22:38

Four Presentations Including Results of Phase 2b Randomized, Open-Label Study of Lower Doses of Quizartinib in FLT3 ITD Positive Relapsed Refractory Acute Myeloid Leukemia (AML) Patients SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55(th) Annual ASH Conference in New...

2013-12-09 14:01:57

Findings from nationwide study led by Children's Mercy researcher highlighted at American Society of Hematology Meeting The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML). Post-treatment relapse rates are a major indicator of potential for long-term survival in children with the disease....

2013-12-09 12:26:23

First patients dosed in Phase 2 dose confirmation trial SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today presented data at the 2013 American Society of Hematology (ASH) Annual Meeting demonstrating promising clinical response rates in patients with myelodysplastic syndromes (MDS) patients treated with mocetinostat in combination with azacitidine. Separately, Mirati announced that it has dosed the first patients in its Phase 2 dose...

2013-12-09 08:30:29

Findings from nationwide study led by Children's Mercy researcher highlighted at American Society of Hematology Meeting KANSAS CITY, Mo., Dec. 9, 2013 /PRNewswire/ -- The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML). Post-treatment relapse rates are a major indicator of potential for...

2013-12-09 08:27:47

OXFORD, England and BERLIN CHEMIE/MENARINI, Germany, December 9, 2013 /PRNewswire/ -- Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) announce today that they have designated a novel enhanced antibody targeting acute myeloid leukemia (AML) as the first clinical development candidate under the companies' strategic oncology collaboration. The companies have initiated formal regulatory enabling studies to support an application for a clinical phase I trial in AML...

2013-12-09 08:27:09

Initial Data Demonstrate Safety and Antileukemic Activity in Older Patients with Acute Myeloid Leukemia NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, were presented in a poster session on Saturday, December 7, 2013 at the American Society of Hematology's (ASH) 55th Annual Meeting and...

2013-12-05 12:29:45

WHITE PLAINS, N.Y., Dec. 5, 2013 /PRNewswire/ -- Many researchers funded by The Leukemia & Lymphoma Society (LLS) will be among those presenting exciting new directions in blood cancer research at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans in early December. The meeting takes place from December 7-10 at the Ernest N. Morial Convention Center. Advances in immune-stimulating therapies, moleculary-targeted drug therapies, including...

2013-12-05 08:30:13

Live Webcast from New York on Wednesday, December 11th SAN DIEGO, Dec. 5, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host an Analyst and Investor Day on Thursday, December 11, 2013 from 12:00 noon to 2:00 p.m. Eastern time in New York City. The event will feature updates by Daniel P. Gold, Ph.D., President and Chief Executive Officer, and Robert D. Mass, MD, Chief Medical Officer,...

2013-12-05 08:29:12

SAN DIEGO, Dec. 5, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Oppenheimer 24(th) Annual Healthcare Conference to be held at the Crown Plaza Hotel in New York City, December 10-11, 2013. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug...

2013-12-05 04:20:55

AMSTERDAM, December 5, 2013 /PRNewswire/ -- ~ Prior to the American Society of Hematology Annual Meeting ~ Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces that its lead product inventor, Denis-Claude Roy, MD, Professor of Medicine at the University of Montreal, is providing the following presentation: "Donor lymphocytes selectively photodepleted of alloreactive T cells can fight...